Company profile
Harmony Biosciences Holdings, Inc.
NASDAQ: HRMY · Healthcare · Biotechnology
#166 of 1,418 Healthcare companies by revenue68th-percentile growth
EA Score
76B+FH 87DQ 65GM 69SS 64
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$899.1M
Rev growth YoY (TTM)
+20.7%
Net income (FY)
$158.7M
Employees
293
as of 2026-08-09
Market cap
$2.2B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$868.5M$868.5M2025
Net income$158.7M$158.7M2025
Operating income$208.5M$208.5M2025
Total assets$1.3B$1.3B2025
Liabilities$401.4M$401.4M2025
Equity$870.2M$870.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Harmony Biosciences Holdings, Inc.’s revenue?
Harmony Biosciences Holdings, Inc. booked $868.5M in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a 18.3% net margin.
Peers · Healthcare
ANI Pharmaceuticals, Inc.82B+Nutex Health, Inc.68BBioCryst Pharmaceuticals, Inc.76B+Innovage Holding Corp.68BVarex Imaging Corporation67BVerano Holdings Corp59CNeighbors
Montgomery →Key facts
CEOJeffrey Dayno
SectorHealthcare
IndustryBiotechnology
HeadquartersPlymouth Meeting, PA
ExchangeNASDAQ: HRMY
Employees293
IPO date2020-08-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.